The discovery and development of rivaroxaban

被引：26

作者：

Misselwitz, Frank ^{[2
]}

Berkowitz, Scott D. ^{[1
]}

Perzborn, Elisabeth ^{[3
]}

机构：

[1] Bayer HealthCare Pharmaceut, Global Clin Dev, Cardiovasc & Coagulat Therapeut Area, Thrombosis & Hemostasis Grp, Montville, NJ 07045 USA

[2] Bayer HealthCare, Global Clin Dev, Therapeut Area Cardiovasc & Coagulat, Wuppertal, Germany

[3] Bayer HealthCare, Global Clin Dev, Cardiovasc Pharmacol, Bayer HealthCare Pharmaceut, Wuppertal, Germany

来源：

PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010 | 2011年 / 1222卷

关键词：

anticoagulant; discovery; Factor Xa; rivaroxaban; FACTOR-XA INHIBITOR; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM RISK; ORAL ANTICOAGULANT-THERAPY; CORONARY-ARTERY PATENCY; PROCOAGULANT ACTIVITY; DOUBLE-BLIND; BAY; 59-7939; IN-VITRO; SELECTIVE-INHIBITION;

D O I：

10.1111/j.1749-6632.2011.05971.x

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Thromboembolic conditions present a considerable challenge to healthcare services because they are associated with substantial morbidity and mortality. The mainstays of prevention and treatment are anticoagulants and antiplatelet agents. Established anticoagulants have drawbacks that make their use difficult to manage and sustain. This has stimulated the search for new oral anticoagulants that are more convenient and yet still effective. This paper describes the development and future potential of rivaroxaban (Xarelto (TM); Bayer Schering Pharma AG, Berlin, Germany)-the first oral, direct Factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery.

引用

页码：64 / 75

页数：12

共 87 条

[81]

TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718

[82] Treatment and prevention of heparin-induced thrombocytopenia [J].